Under the MoU, both parties will work on terms to establish a cooperative relationship in the field of veterinary science to complete a pilot study to determine the efficacy of cannabidiol (CBD) treatment for epilepsy in dogs in 2019.
The MoU builds on CannPal’s current research pipeline which includes the phase Ib study for CPAT-01, a pain control in dogs, and its extension CPAT-01C for cats.
CannPal's managing director Layton Mills said: “This MoU with the University of Melbourne is the latest in a long line of strategic agreements CannPal has entered, to establish the company as a global leader in cannabinoid-derived therapeutics for companion animals.
“It’s further validation of the high-quality research we are undertaking and we look forward to working with the University on this project.”
Cannabidiol has a number of reported health benefits
Cannabidiol is a non-psychoactive compound derived from cannabis with a number of reported health benefits which include anxiolytic, anti-inflammatory, antibacterial and antiseizure properties.
In June 2018, the US Food and Drug Administration (FDA) approved Epidiolex (cannabidiol) oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy in human patients of 2 years of age and older.
This is the first FDA-approved drug that contains a purified drug substance derived from marijuana and the Company is hopeful that similar effects using cannabinoids can be seen in dogs with idiopathic epilepsy.